Why not? Sarep­ta’s third Duchenne MD drug sails to ac­cel­er­at­ed ap­proval

Sarep­ta may be run­ning in­to some trou­ble with its next-gen gene ther­a­py ap­proach to Duchenne mus­cu­lar dy­s­tro­phy. But when it comes to an­ti­sense oligonu­cleotides, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER